CTLA4 and rheumatoid arthritis: Thus, if the CTLA-4 blockade enhances the intratumoral T-effector/T-regulator cell ratio in cancer patients, by depleting T-regulator cells [108], immunotherapy modulating CTLA-4 (such as abatacept) improves the regulatory T-cell inhibitory function in rheumatoid arthritis patients [109].